Similar articles for PMID: 21176172

Year	Number of Results
1997	1
2000	1
2002	1
2003	1
2004	5
2005	3
2006	7
2007	6
2008	10
2009	6
2010	6
2011	4
2012	6
2013	13
2014	7
2015	5
2016	4
2017	1
2018	4
2019	4
2022	2

1

Curatolo P, D'Agati E, Moavero R. Curatolo P, et al. Ital J Pediatr. 2010 Dec 22;36(1):79. doi: 10.1186/1824-7288-36-79. Ital J Pediatr. 2010. PMID: 21176172 Free PMC article. Review.

2

Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.

Husarova V, Bittsansky M, Ondrejka I, Dobrota D. Husarova V, et al. Psychiatry Res. 2014 Apr 30;222(1-2):75-83. doi: 10.1016/j.pscychresns.2014.03.003. Epub 2014 Mar 15. Psychiatry Res. 2014. PMID: 24679996

3

The neurobiology of attention-deficit/hyperactivity disorder.

Chamberlain SR, Robbins TW, Sahakian BJ. Chamberlain SR, et al. Biol Psychiatry. 2007 Jun 15;61(12):1317-9. doi: 10.1016/j.biopsych.2007.04.009. Biol Psychiatry. 2007. PMID: 17556026 No abstract available.

4

MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder.

Schweren LJ, de Zeeuw P, Durston S. Schweren LJ, et al. Eur Neuropsychopharmacol. 2013 Oct;23(10):1151-64. doi: 10.1016/j.euroneuro.2012.10.014. Epub 2012 Nov 17. Eur Neuropsychopharmacol. 2013. PMID: 23165220 Review.

5

Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination.

Smith A, Cubillo A, Barrett N, Giampietro V, Simmons A, Brammer M, Rubia K. Smith A, et al. Biol Psychiatry. 2013 Oct 15;74(8):615-22. doi: 10.1016/j.biopsych.2013.03.030. Epub 2013 May 31. Biol Psychiatry. 2013. PMID: 23731741 Clinical Trial.

6

[Autism and attention deficit hyperactivity disorder: pharmacological intervention].

Fernández-Jaén A, Martín Fernández-Mayoralas D, Fernández-Perrone AL, Calleja-Pérez B, Muñoz-Jareño N, López-Arribas S. Fernández-Jaén A, et al. Rev Neurol. 2013 Sep 6;57 Suppl 1:S205-10. Rev Neurol. 2013. PMID: 23897149 Free article. Review. Spanish.

7

A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.

Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK. Ni HC, et al. Int J Neuropsychopharmacol. 2013 Oct;16(9):1959-73. doi: 10.1017/S1461145713000357. Epub 2013 May 14. Int J Neuropsychopharmacol. 2013. PMID: 23672818 Free article. Clinical Trial.

8

Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.

Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH. Schulz KP, et al. Arch Gen Psychiatry. 2012 Sep;69(9):952-61. doi: 10.1001/archgenpsychiatry.2011.2053. Arch Gen Psychiatry. 2012. PMID: 22945622 Clinical Trial.

9

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.

Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P. Roskell NS, et al. Curr Med Res Opin. 2014 Aug;30(8):1673-85. doi: 10.1185/03007995.2014.904772. Epub 2014 Apr 15. Curr Med Res Opin. 2014. PMID: 24627974 Review.

10

[New therapeutic options in the treatment of attention deficit/hyperactivity disorder].

Artigas Pallares J. Artigas Pallares J. Rev Neurol. 2004 Feb;38 Suppl 1:S117-23. Rev Neurol. 2004. PMID: 15011165 Free article. Spanish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed